UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 105

Sortiert nach

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

PloS one, 2011-09, Vol.6 (9), p.e22871-e22871

2011

Link zum Volltext

Verfügbarkeit prüfen

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Emerging infectious diseases, 2020-08, Vol.26 (8), p.1792-1800

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

PloS one, 2012-05, Vol.7 (5), p.e36673-e36673

2012

Link zum Volltext

Verfügbarkeit prüfen

Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant

Microbiology spectrum, 2022-10, Vol.10 (5), p.e0192222-e0192222

2022

Link zum Volltext

Verfügbarkeit prüfen

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

Clinical journal of the American Society of Nephrology, 2011-07, Vol.6 (7), p.1700-1707

2011

Link zum Volltext

Verfügbarkeit prüfen

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study

PloS one, 2017-12, Vol.12 (12), p.e0187517-e0187517

2017

Link zum Volltext

Verfügbarkeit prüfen

Choice of effect measure in HIV randomized trials

AIDS (London), 2015-09, Vol.29 (15), p.2057-2060

Flandre, Philippe

2015

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test

Life (Basel, Switzerland), 2022-12, Vol.12 (12), p.2064

2022

Link zum Volltext

Verfügbarkeit prüfen

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

Journal of clinical epidemiology, 2018-04, Vol.96, p.63-72

2018

Link zum Volltext

Verfügbarkeit prüfen

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

PloS one, 2011-09, Vol.6 (9), p.e24798

2011

Link zum Volltext

Verfügbarkeit prüfen

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

PloS one, 2012-07, Vol.7 (7), p.e41390-e41390

2012

Link zum Volltext

Verfügbarkeit prüfen

Some current issues in the design of HIV noninferiority trials

AIDS (London), 2014-08, Vol.28 (13), p.1921-1929

FLANDRE, Philippe

2014

Link zum Volltext

Verfügbarkeit prüfen

Design of HIV noninferiority trials: where are we going?

AIDS (London), 2013-02, Vol.27 (4), p.653-657

FLANDRE, Philippe

2013

Link zum Volltext

Verfügbarkeit prüfen

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Antimicrobial Agents and Chemotherapy, 2009-07, Vol.53 (7), p.2934-2939

2009

Link zum Volltext

Verfügbarkeit prüfen

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

PloS one, 2015-06, Vol.10 (6), p.e0127816-e0127816

2015

Link zum Volltext

Verfügbarkeit prüfen

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set

PloS one, 2013-03, Vol.8 (3), p.e59014

2013

Link zum Volltext

Verfügbarkeit prüfen

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

PloS one, 2013-10, Vol.8 (10), p.e74078-e74078

2013

Link zum Volltext

Verfügbarkeit prüfen

Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients

Antimicrobial Agents and Chemotherapy, 2008-09, Vol.52 (9), p.3237-3243

2008

Link zum Volltext

Verfügbarkeit prüfen

Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy

Antimicrobial Agents and Chemotherapy, 2010-11, Vol.54 (11), p.4910-4913

2010

Link zum Volltext

Verfügbarkeit prüfen

Clinically Relevant Genotype Interpretation of Resistance to Didanosine

Antimicrobial Agents and Chemotherapy, 2005-05, Vol.49 (5), p.1739-1744

2005

Link zum Volltext

Verfügbarkeit prüfen

Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir

Antimicrobial Agents and Chemotherapy, 2008-02, Vol.52 (2), p.491-496

2008

Link zum Volltext

Verfügbarkeit prüfen

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

PloS one, 2013-01, Vol.8 (1), p.e54381-e54381

2013

Link zum Volltext

Verfügbarkeit prüfen

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

Current HIV research, 2011-01, Vol.9 (1), p.31

2011

Link zum Volltext

Verfügbarkeit prüfen

The Short-Term and Long-Term Hazard Ratio Model: Parameterization Inconsistency

The American statistician, 2021-10, Vol.75 (4), p.376-382

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021)

Journal of Virology, 2005-08, Vol.79 (15), p.9572-9578

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 105

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library Journals【キャンパス外アクセス可】

SpracheFranzösisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(93)

Publikationsform

Artikel
(105)

Sprache

Englisch
(105)

Erscheinungsjahr

n.n

Thema

Science & Technology
(89)
Humans
(80)
Life Sciences & Biomedicine
(76)
Infectious Diseases
(63)
Hiv Infections - Drug Therapy
(61)
Biological And Medical Sciences
(47)
Medical Sciences
(47)
Male
(46)
Female
(43)
Virology
(38)
Hiv Infections - Virology
(36)
Hiv-1 - Drug Effects
(35)
Hiv-1 - Genetics
(35)
Antiviral Agents
(33)
Adult
(32)
Pharmacology. Drug Treatments
(32)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(31)
Hiv
(31)
Human Immunodeficiency Virus
(31)
Microbiology
(31)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study

Choice of effect measure in HIV randomized trials

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

Some current issues in the design of HIV noninferiority trials

Design of HIV noninferiority trials: where are we going?

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients

Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy

Clinically Relevant Genotype Interpretation of Resistance to Didanosine

Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

The Short-Term and Long-Term Hazard Ratio Model: Parameterization Inconsistency

Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021)

Aktive Filter

Suchergebnisse filtern